Thalidomide and its analogues in the treatment of Multiple Myeloma

  • Latif T
  • Chauhan N
  • Khan R
  • et al.
N/ACitations
Citations of this article
110Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Multiple myeloma is an incurable malignant disorder of mature B-cells that predominantly affects the elderly. The immunomodulatory drug (IMiD) thalidomide and its newer analogs demonstrate increased antitumor activity, and have had a positive impact on the natural history of multiple myeloma. Recent advances in the clinical application of these agents and in our understanding of their mechanism of action, and toxicity have made safer and smarter use of these drugs possible. This review discusses the available information regarding mechanisms of action, toxicity and clinical results on thalidomide, lenalidomide and pomalidomide in the therapy of multiple myeloma.

Cite

CITATION STYLE

APA

Latif, T., Chauhan, N., Khan, R., Moran, A., & Usmani, S. Z. (2012). Thalidomide and its analogues in the treatment of Multiple Myeloma. Experimental Hematology & Oncology, 1(1), 27. https://doi.org/10.1186/2162-3619-1-27

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free